Exit strategy.
There have been some credible efforts to handicap the post-approval share price here on the board. I don't see how it's possible to estimate revenue without knowing how the application is worded and the market which NWBO intends to serve. There are a host of other variables as well which will affect share price after approval. With the possibility of a short squeeze I'm setting some GTC orders at 60, 80, and 100 so I don't miss a spike. For clarity, I do not expect those orders to trigger.
Major institutionts have teams of major league financial analysts and I believe a stable valuation will quickly emerge. I plan to sell nothing before a week or 10 days after the first RA approval. (GTC orders excepted)
I expect a stable SP of $10 to $30 for the first few weeks and months after approval.
I predict that as more and more financial analysts become acquainted with the finer points of micorbiology, neuro-oncology dendritic cell activation and what the hell a lysate is, the SP will be steadily driven up for many, many months.
I think the foundational nature of this treatment will drive SP past $200. Probably a few years down the road, but I don't think NWBO will take as long as Google or Amazon or Tesla to see such a valuation. The market moves faster than it did 20 years ago.
Bullish
Market Data 
Markets 
AI
